Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
02 2020
Historique:
entrez: 30 1 2020
pubmed: 30 1 2020
medline: 1 9 2020
Statut: ppublish

Résumé

Scarce data exist on coronary events following transcatheter aortic valve replacement (TAVR), and no study has determined the factors associated with poorer outcomes in this setting. This study sought to determine the clinical characteristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) events following TAVR. Multicenter cohort study including a total of 270 patients presenting an ACS after a median time of 12 (interquartile range, 5-17) months post-TAVR. Post-ACS death, myocardial infarction, stroke, and overall major adverse cardiovascular or cerebrovascular events were recorded. The ACS clinical presentation consisted of non-ST-segment-elevation myocardial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%). An invasive strategy was used in 163 patients (60.4%), and a percutaneous coronary intervention was performed in 97 patients (35.9%). Coronary access issues were observed in 2.5% and 2.1% of coronary angiography and percutaneous coronary intervention procedures, respectively. The in-hospital mortality rate was 10.0%, and at a median follow-up of 17 (interquartile range, 5-32) months, the rates of death, stroke, myocardial infarction, and major adverse cardiovascular or cerebrovascular events were 43.0%, 4.1%, 15.2%, and 52.6%, respectively. By multivariable analysis, revascularization at ACS time was associated with a reduction of the risk of all-cause death (hazard ratio, 0.54 [95% CI, 0.36-0.81] ACS events in TAVR recipients exhibited specific characteristics (ACS presentation, low use of invasive procedures, coronary access issues) and were associated with a poor prognosis, with a very high in-hospital and late death rate. STEMI and the lack of coronary revascularization determined an increased risk. These results should inform future studies to improve both the prevention and management of ACS post-TAVR.

Sections du résumé

BACKGROUND
Scarce data exist on coronary events following transcatheter aortic valve replacement (TAVR), and no study has determined the factors associated with poorer outcomes in this setting. This study sought to determine the clinical characteristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) events following TAVR.
METHODS
Multicenter cohort study including a total of 270 patients presenting an ACS after a median time of 12 (interquartile range, 5-17) months post-TAVR. Post-ACS death, myocardial infarction, stroke, and overall major adverse cardiovascular or cerebrovascular events were recorded.
RESULTS
The ACS clinical presentation consisted of non-ST-segment-elevation myocardial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%). An invasive strategy was used in 163 patients (60.4%), and a percutaneous coronary intervention was performed in 97 patients (35.9%). Coronary access issues were observed in 2.5% and 2.1% of coronary angiography and percutaneous coronary intervention procedures, respectively. The in-hospital mortality rate was 10.0%, and at a median follow-up of 17 (interquartile range, 5-32) months, the rates of death, stroke, myocardial infarction, and major adverse cardiovascular or cerebrovascular events were 43.0%, 4.1%, 15.2%, and 52.6%, respectively. By multivariable analysis, revascularization at ACS time was associated with a reduction of the risk of all-cause death (hazard ratio, 0.54 [95% CI, 0.36-0.81]
CONCLUSIONS
ACS events in TAVR recipients exhibited specific characteristics (ACS presentation, low use of invasive procedures, coronary access issues) and were associated with a poor prognosis, with a very high in-hospital and late death rate. STEMI and the lack of coronary revascularization determined an increased risk. These results should inform future studies to improve both the prevention and management of ACS post-TAVR.

Identifiants

pubmed: 31992059
doi: 10.1161/CIRCINTERVENTIONS.119.008620
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e008620

Auteurs

Laurent Faroux (L)

Quebec Heart and Lung Institute, Laval University, Canada (L.F., D.d.V., T.C., J.R.-C.).

Erika Munoz-Garcia (E)

Hospital Universitario Virgen de la Victoria, Málaga, Spain (E.M.-G., A.M.-G.).

Vicenç Serra (V)

Hospital Universitari Vall d'Hebron, Barcelona, Spain (V.S., B.G.d.B., M.B.-O.).

Alberto Alperi (A)

Hospital Universitario Central de Asturias, Oviedo, Spain (A.A., C.M.).

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Universitario Clínico San Carlos, Madrid, Spain (L.N.-F., G.A.).

Quentin Fischer (Q)

Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France (Q.F., M.U.).

Gabriela Veiga (G)

Hospital Marques de Valdecilla, Santander, Spain (G.V., V.F.-S.).

Pierre Donaint (P)

Reims University Hospital, Reims, France (P.D., D.M.).

Lluis Asmarats (L)

Hospital Santa Creu i Sant Pau, Barcelona, Spain (L.A., P.C.).

Victoria Vilalta (V)

Hospital Germans Trias i Pujol Badalona, Spain (V.V., E.F.-N.).

Chekrallah Chamandi (C)

Hôpital Georges Pompidou, Paris, France (C.C.).

Ander Regueiro (A)

Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain (A.R., M.S.).

Enrique Gutiérrez (E)

Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain (E.G., M.T.).

Antonio Munoz-Garcia (A)

Hospital Universitario Virgen de la Victoria, Málaga, Spain (E.M.-G., A.M.-G.).

Bruno Garcia Del Blanco (B)

Hospital Universitari Vall d'Hebron, Barcelona, Spain (V.S., B.G.d.B., M.B.-O.).

Montserrat Bach-Oller (M)

Hospital Universitari Vall d'Hebron, Barcelona, Spain (V.S., B.G.d.B., M.B.-O.).

Cesar Moris (C)

Hospital Universitario Central de Asturias, Oviedo, Spain (A.A., C.M.).

German Armijo (G)

Cardiovascular Institute, Hospital Universitario Clínico San Carlos, Madrid, Spain (L.N.-F., G.A.).

Marina Urena (M)

Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France (Q.F., M.U.).

Victor Fradejas-Sastre (V)

Hospital Marques de Valdecilla, Santander, Spain (G.V., V.F.-S.).

Damien Metz (D)

Reims University Hospital, Reims, France (P.D., D.M.).

Pablo Castillo (P)

Hospital Santa Creu i Sant Pau, Barcelona, Spain (L.A., P.C.).

Eduard Fernandez-Nofrerias (E)

Hospital Germans Trias i Pujol Badalona, Spain (V.V., E.F.-N.).

Manel Sabaté (M)

Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain (A.R., M.S.).

Maria Tamargo (M)

Instituto de Investigación Sanitaria Gregorio Marañon, Madrid, Spain (E.G., M.T.).

David Del Val (D)

Quebec Heart and Lung Institute, Laval University, Canada (L.F., D.d.V., T.C., J.R.-C.).

Thomas Couture (T)

Quebec Heart and Lung Institute, Laval University, Canada (L.F., D.d.V., T.C., J.R.-C.).

Josep Rodes-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Canada (L.F., D.d.V., T.C., J.R.-C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH